
Albireo Pharma ALBO
Quartalsbericht 2022-Q3
hinzugefügt 08.11.2022
Albireo Pharma Gesamtes Eigenkapital 2011-2026 | ALBO
Gesamtes Eigenkapital Jährlich Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 176 M | 181 M | 93.2 M | 123 M | 65.3 M | 37 M | -8.74 M | 22.8 M | 32.6 M | 31 M | 37.1 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 181 M | -8.74 M | 71.8 M |
Gesamtes Eigenkapital Vierteljährlich Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 100 M | 114 M | 148 M | 176 M | 182 M | 114 M | 148 M | 181 M | 181 M | 181 M | 181 M | 93.2 M | 93.2 M | 93.2 M | 93.2 M | 123 M | 123 M | 123 M | 123 M | 65.3 M | 65.3 M | 65.3 M | 65.3 M | 37 M | 37 M | 37 M | 37 M | -8.74 M | 39.6 M | 39.6 M | 36.5 M | -2.33 M | 22.8 M | 22.8 M | 18.9 M | 30.4 M | 32.6 M | 32.6 M | 32.6 M | 31 M | 31 M | 31 M | 27.9 M | 33.4 M | 37.1 M | 37.1 M | 33.4 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 182 M | -8.74 M | 75.2 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
ADMA Biologics
ADMA
|
477 M | $ 15.57 | -5.89 % | $ 3.71 B | ||
|
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
967 M | $ 3.58 | -1.38 % | $ 1.07 B | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Anika Therapeutics
ANIK
|
212 M | $ 14.19 | -1.18 % | $ 208 M | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Aptorum Group Limited
APM
|
21.1 M | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
370 M | $ 20.24 | 1.91 % | $ 2.55 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
404 M | $ 75.6 | -1.22 % | $ 1.46 B | ||
|
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.5 | -8.28 % | $ 383 M | ||
|
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
88.3 M | $ 159.87 | -2.57 % | $ 7.95 B | ||
|
BridgeBio Pharma
BBIO
|
-2.09 B | $ 65.73 | -1.22 % | $ 12.6 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-7.76 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | ||
|
Equillium
EQ
|
22.6 M | $ 1.79 | 2.29 % | $ 62.2 M | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
22 M | $ 2.72 | -3.31 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 60.54 | 0.18 % | $ 11.6 B | ||
|
Burford Capital Limited
BUR
|
1.7 B | $ 8.26 | -1.31 % | $ 1.36 B | ||
|
Cabaletta Bio
CABA
|
236 M | $ 3.2 | -6.71 % | $ 3.74 M | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
-160 M | $ 2.93 | -8.44 % | $ 1.05 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Capricor Therapeutics
CAPR
|
22.6 M | $ 25.74 | 0.94 % | $ 689 M |